Image For Activity Cover
Refining Strategies for the Management of Hypophosphatemic Bone Disease
Course Description

In this recording, the faculty discussed:

  • The Diagnosis & Medical Management of Hypophosphatemia
  • X-linked Hypophosphatemia: From Childhood to Adulthood
  • Analyzing Optimal Treatment Options for the Management of Hypophosphatemia & XLH

This course was a virtual live CME-certified Ancillary Symposium to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Ultragenyx Pharmaceutical Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).

Learning Objectives

Upon successful completion these educational sessions, participants should be better able to:

  • Review the relationship between hypophosphatemia and X-linked hypophosphatemia.
  • Analyze the importance of early diagnosis for hypophosphatemia and XLH for patient outcomes and quality of life.
  • Evaluate emerging techniques and practical challenges in managing hypophosphatemia and XLH in children and adults.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty and Disclosures

Thomas O. Carpenter, MD - Program Chair
Professor of Pediatrics (Endocrinology) and of Orthopaedics and Rehabilitation
Clinical Professor of Nursing
Director Yale Center for X-Linked Hypophosphatemia
Medical Director, Hospital Research Unit
Yale School of Medicine
New Haven, CT

Farzana Perwad, MD
Chief, Division of Nephrology
University of California San Francisco
San Francisco, CA

Leanne M. Ward, MD
Professor of Pediatrics
University of Ottawa
Ottawa, ON

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships:
Thomas O. Carpenter, MD: Advisory Board Member, Inozyme; Consultant, Regeneron Pharmaceuticals, Ultragenyx, Up To Date, Inozyme, Kyowa Kirin Pharma; Grant Recipient, Ultragenyx; Research Investigator, Ultragenyx
Farzana Perwad, MD: Speaker, Ultragenyx
Leanne M. Ward, MD: Advisory Board Member, Ultragenyx; Consultant, Ultragenyx; Research Investigator, Ultragenyx

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept
  • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
  • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
  • Amy Rothberg, MD: Spouse, consultant of Merck
  • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Ultragenyx Pharmaceutical Inc.

Summary
Availability: On-Demand
Available Mar 26, 2021 to Mar 31, 2022
Cost: FREE
Credit Offered: 1.5 AMA PRA Category 1 Credits
1.5 ABIM-MOC Points
1.5 Participation Credits
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By